Ovensa Inc. is a preclinical stage biotech company advancing the development of its siRNA lead candidate silencing galectin-1 (Gal-1) overexpression in the tumor microenvironment to improve therapeutic outcomes of immuno-oncology checkpoint inhibitors as a combination therapy in head and neck cancer. Ovensa currently works with pharmaceutical companies to formulate their mRNA, siRNA or other drugs into nanoparticles using Ovensa's TRIOZAN™ drug delivery platform for CNS delivery or for targeting other organs.

Ovensa Inc. Logo



Event details

Date: June 10 - 17, 2021

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences


30 in total